These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36315443)

  • 1. Correction to: Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.
    Schizophr Bull; 2023 Mar; 49(2):534-537. PubMed ID: 36315443
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.
    Fraguas D; Díaz-Caneja CM; Pina-Camacho L; Umbricht D; Arango C
    Schizophr Bull; 2019 Jan; 45(1):57-68. PubMed ID: 29370436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence.
    Czobor P; Kakuszi B; Bitter I
    Schizophr Bull; 2022 Nov; 48(6):1228-1240. PubMed ID: 35713342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
    Leucht S; Leucht C; Huhn M; Chaimani A; Mavridis D; Helfer B; Samara M; Rabaioli M; Bächer S; Cipriani A; Geddes JR; Salanti G; Davis JM
    Am J Psychiatry; 2017 Oct; 174(10):927-942. PubMed ID: 28541090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response.
    Leucht S; Chaimani A; Leucht C; Huhn M; Mavridis D; Helfer B; Samara M; Cipriani A; Geddes JR; Salanti G; Davis JM
    Schizophr Res; 2018 Nov; 201():315-323. PubMed ID: 29804928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials.
    Sabe M; Zhao N; Crippa A; Strauss GP; Kaiser S
    Int J Neuropsychopharmacol; 2021 Aug; 24(8):601-614. PubMed ID: 33890987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.
    Siafis S; Çıray O; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S
    Mol Autism; 2020 Aug; 11(1):66. PubMed ID: 32847616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective noradrenaline reuptake inhibitors for schizophrenia.
    Matthews PRL; Horder J; Pearce M
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010219. PubMed ID: 29368813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis.
    Leucht S; Chaimani A; Mavridis D; Leucht C; Huhn M; Helfer B; Samara M; Cipriani A; Geddes JR; Davis JM
    Neuropsychopharmacology; 2019 Oct; 44(11):1955-1966. PubMed ID: 31212302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials.
    Miura I; Nosaka T; Yabe H; Hagi K
    Int J Neuropsychopharmacol; 2021 Mar; 24(3):200-215. PubMed ID: 33151310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis.
    Siskind DJ; Wu BT; Wong TT; Firth J; Kisely S
    Lancet Psychiatry; 2020 Sep; 7(9):762-774. PubMed ID: 32828166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.
    Beck K; Hindley G; Borgan F; Ginestet C; McCutcheon R; Brugger S; Driesen N; Ranganathan M; D'Souza DC; Taylor M; Krystal JH; Howes OD
    JAMA Netw Open; 2020 May; 3(5):e204693. PubMed ID: 32437573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
    Welge JA; Keck PE
    Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of the placebo response in clinical trials on Parkinson's disease: A meta-analysis.
    Shin CW; Hahn S; Park BJ; Kim JM; Park EO; Jeon B
    Parkinsonism Relat Disord; 2016 Aug; 29():83-9. PubMed ID: 27237106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Z-drug for schizophrenia: A systematic review and meta-analysis.
    Kishi T; Inada K; Matsui Y; Iwata N
    Psychiatry Res; 2017 Oct; 256():365-370. PubMed ID: 28686934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials.
    Corponi F; Serretti A; Montgomery S; Fabbri C
    Int Clin Psychopharmacol; 2017 Nov; 32(6):309-318. PubMed ID: 28727644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials.
    Osugo M; Whitehurst T; Shatalina E; Townsend L; O'Brien O; Mak TLA; McCutcheon R; Howes O
    Neurosci Biobehav Rev; 2022 Apr; 135():104568. PubMed ID: 35131396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are Patients With
    Palermo S; Giovannelli F; Bartoli M; Amanzio M
    Front Pharmacol; 2019; 10():502. PubMed ID: 31156432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.